Provided by Tiger Trade Technology Pte. Ltd.

Compass Therapeutics, Inc.

6.52
+0.30004.82%
Post-market: 6.520.00000.00%19:29 EST
Volume:2.01M
Turnover:13.15M
Market Cap:1.16B
PE:-14.45
High:6.69
Open:6.35
Low:6.29
Close:6.22
52wk High:6.88
52wk Low:1.33
Shares:177.86M
Float Shares:123.05M
Volume Ratio:0.81
T/O Rate:1.63%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4512
EPS(LYR):-0.3594
ROE:-37.82%
ROA:-23.47%
PB:5.53
PE(LYR):-18.14

Loading ...

Company Profile

Company Name:
Compass Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
2014
Employees:
35
Office Location:
80 Guest Street,Suite 601,Boston,Massachusetts,United States
Zip Code:
02135
Fax:
- -
Introduction:
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.